List of Tables
Table 1. Global Pelvic Cancer Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Pelvic Cancer Drug Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Pelvic Cancer Drug Market Competitive Situation by Manufacturers in 2024
Table 4. Global Pelvic Cancer Drug Sales (kg) of Key Manufacturers (2020-2025)
Table 5. Global Pelvic Cancer Drug Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Pelvic Cancer Drug Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Pelvic Cancer Drug Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Pelvic Cancer Drug Average Price (US$/g) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Pelvic Cancer Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Pelvic Cancer Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Pelvic Cancer Drug, Product Type & Application
Table 12. Global Key Manufacturers of Pelvic Cancer Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Pelvic Cancer Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pelvic Cancer Drug as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Pelvic Cancer Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Pelvic Cancer Drug Sales by Region (2020-2025) & (kg)
Table 18. Global Pelvic Cancer Drug Sales Market Share by Region (2020-2025)
Table 19. Global Pelvic Cancer Drug Sales by Region (2026-2031) & (kg)
Table 20. Global Pelvic Cancer Drug Sales Market Share by Region (2026-2031)
Table 21. Global Pelvic Cancer Drug Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Pelvic Cancer Drug Revenue Market Share by Region (2020-2025)
Table 23. Global Pelvic Cancer Drug Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Pelvic Cancer Drug Revenue Market Share by Region (2026-2031)
Table 25. North America Pelvic Cancer Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Pelvic Cancer Drug Sales by Country (2020-2025) & (kg)
Table 27. North America Pelvic Cancer Drug Sales by Country (2026-2031) & (kg)
Table 28. North America Pelvic Cancer Drug Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Pelvic Cancer Drug Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Pelvic Cancer Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Pelvic Cancer Drug Sales by Country (2020-2025) & (kg)
Table 32. Europe Pelvic Cancer Drug Sales by Country (2026-2031) & (kg)
Table 33. Europe Pelvic Cancer Drug Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Pelvic Cancer Drug Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Pelvic Cancer Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Pelvic Cancer Drug Sales by Region (2020-2025) & (kg)
Table 37. Asia Pacific Pelvic Cancer Drug Sales by Region (2026-2031) & (kg)
Table 38. Asia Pacific Pelvic Cancer Drug Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Pelvic Cancer Drug Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Pelvic Cancer Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Pelvic Cancer Drug Sales by Country (2020-2025) & (kg)
Table 42. Latin America Pelvic Cancer Drug Sales by Country (2026-2031) & (kg)
Table 43. Latin America Pelvic Cancer Drug Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Pelvic Cancer Drug Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Pelvic Cancer Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Pelvic Cancer Drug Sales by Country (2020-2025) & (kg)
Table 47. Middle East and Africa Pelvic Cancer Drug Sales by Country (2026-2031) & (kg)
Table 48. Middle East and Africa Pelvic Cancer Drug Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Pelvic Cancer Drug Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Pelvic Cancer Drug Sales (kg) by Type (2020-2025)
Table 51. Global Pelvic Cancer Drug Sales (kg) by Type (2026-2031)
Table 52. Global Pelvic Cancer Drug Sales Market Share by Type (2020-2025)
Table 53. Global Pelvic Cancer Drug Sales Market Share by Type (2026-2031)
Table 54. Global Pelvic Cancer Drug Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Pelvic Cancer Drug Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Pelvic Cancer Drug Revenue Market Share by Type (2020-2025)
Table 57. Global Pelvic Cancer Drug Revenue Market Share by Type (2026-2031)
Table 58. Global Pelvic Cancer Drug Price (US$/g) by Type (2020-2025)
Table 59. Global Pelvic Cancer Drug Price (US$/g) by Type (2026-2031)
Table 60. Global Pelvic Cancer Drug Sales (kg) by Application (2020-2025)
Table 61. Global Pelvic Cancer Drug Sales (kg) by Application (2026-2031)
Table 62. Global Pelvic Cancer Drug Sales Market Share by Application (2020-2025)
Table 63. Global Pelvic Cancer Drug Sales Market Share by Application (2026-2031)
Table 64. Global Pelvic Cancer Drug Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Pelvic Cancer Drug Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Pelvic Cancer Drug Revenue Market Share by Application (2020-2025)
Table 67. Global Pelvic Cancer Drug Revenue Market Share by Application (2026-2031)
Table 68. Global Pelvic Cancer Drug Price (US$/g) by Application (2020-2025)
Table 69. Global Pelvic Cancer Drug Price (US$/g) by Application (2026-2031)
Table 70. F. Hoffmann-La Roche Ltd Company Information
Table 71. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 72. F. Hoffmann-La Roche Ltd Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 73. F. Hoffmann-La Roche Ltd Pelvic Cancer Drug Product
Table 74. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 75. Pfizer Inc. Company Information
Table 76. Pfizer Inc. Description and Business Overview
Table 77. Pfizer Inc. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 78. Pfizer Inc. Pelvic Cancer Drug Product
Table 79. Pfizer Inc. Recent Developments/Updates
Table 80. GSK plc Company Information
Table 81. GSK plc Description and Business Overview
Table 82. GSK plc Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 83. GSK plc Pelvic Cancer Drug Product
Table 84. GSK plc Recent Developments/Updates
Table 85. Eli Lilly and Company Company Information
Table 86. Eli Lilly and Company Description and Business Overview
Table 87. Eli Lilly and Company Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 88. Eli Lilly and Company Pelvic Cancer Drug Product
Table 89. Eli Lilly and Company Recent Developments/Updates
Table 90. AstraZeneca Company Information
Table 91. AstraZeneca Description and Business Overview
Table 92. AstraZeneca Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 93. AstraZeneca Pelvic Cancer Drug Product
Table 94. AstraZeneca Recent Developments/Updates
Table 95. Bristol-Myers Squibb Company Company Information
Table 96. Bristol-Myers Squibb Company Description and Business Overview
Table 97. Bristol-Myers Squibb Company Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 98. Bristol-Myers Squibb Company Pelvic Cancer Drug Product
Table 99. Bristol-Myers Squibb Company Recent Developments/Updates
Table 100. Merck & Co., Inc. Company Information
Table 101. Merck & Co., Inc. Description and Business Overview
Table 102. Merck & Co., Inc. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 103. Merck & Co., Inc. Pelvic Cancer Drug Product
Table 104. Merck & Co., Inc. Recent Developments/Updates
Table 105. Novartis AG Company Information
Table 106. Novartis AG Description and Business Overview
Table 107. Novartis AG Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 108. Novartis AG Pelvic Cancer Drug Product
Table 109. Novartis AG Recent Developments/Updates
Table 110. Alnylam Pharmaceuticals, Inc. Company Information
Table 111. Alnylam Pharmaceuticals, Inc. Description and Business Overview
Table 112. Alnylam Pharmaceuticals, Inc. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 113. Alnylam Pharmaceuticals, Inc. Pelvic Cancer Drug Product
Table 114. Alnylam Pharmaceuticals, Inc. Recent Developments/Updates
Table 115. Boehringer Ingelheim International GmbH Company Information
Table 116. Boehringer Ingelheim International GmbH Description and Business Overview
Table 117. Boehringer Ingelheim International GmbH Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 118. Boehringer Ingelheim International GmbH Pelvic Cancer Drug Product
Table 119. Boehringer Ingelheim International GmbH Recent Developments/Updates
Table 120. Advaxis, Inc. Company Information
Table 121. Advaxis, Inc. Description and Business Overview
Table 122. Advaxis, Inc. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 123. Advaxis, Inc. Pelvic Cancer Drug Product
Table 124. Advaxis, Inc. Recent Developments/Updates
Table 125. Teva Pharmaceutical Industries Ltd. Company Information
Table 126. Teva Pharmaceutical Industries Ltd. Description and Business Overview
Table 127. Teva Pharmaceutical Industries Ltd. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 128. Teva Pharmaceutical Industries Ltd. Pelvic Cancer Drug Product
Table 129. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 130. Johnson & Johnson Services, Inc. Company Information
Table 131. Johnson & Johnson Services, Inc. Description and Business Overview
Table 132. Johnson & Johnson Services, Inc. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 133. Johnson & Johnson Services, Inc. Pelvic Cancer Drug Product
Table 134. Johnson & Johnson Services, Inc. Recent Developments/Updates
Table 135. Biocon Company Information
Table 136. Biocon Description and Business Overview
Table 137. Biocon Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 138. Biocon Pelvic Cancer Drug Product
Table 139. Biocon Recent Developments/Updates
Table 140. AbbVie Inc. Company Information
Table 141. AbbVie Inc. Description and Business Overview
Table 142. AbbVie Inc. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 143. AbbVie Inc. Pelvic Cancer Drug Product
Table 144. AbbVie Inc. Recent Developments/Updates
Table 145. Siemens Healthineers Company Information
Table 146. Siemens Healthineers Description and Business Overview
Table 147. Siemens Healthineers Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 148. Siemens Healthineers Pelvic Cancer Drug Product
Table 149. Siemens Healthineers Recent Developments/Updates
Table 150. Gilead Sciences, Inc. Company Information
Table 151. Gilead Sciences, Inc. Description and Business Overview
Table 152. Gilead Sciences, Inc. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 153. Gilead Sciences, Inc. Pelvic Cancer Drug Product
Table 154. Gilead Sciences, Inc. Recent Developments/Updates
Table 155. Sanofi Company Information
Table 156. Sanofi Description and Business Overview
Table 157. Sanofi Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 158. Sanofi Pelvic Cancer Drug Product
Table 159. Sanofi Recent Developments/Updates
Table 160. Bayer AG Company Information
Table 161. Bayer AG Description and Business Overview
Table 162. Bayer AG Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)
Table 163. Bayer AG Pelvic Cancer Drug Product
Table 164. Bayer AG Recent Developments/Updates
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. Pelvic Cancer Drug Distributors List
Table 168. Pelvic Cancer Drug Customers List
Table 169. Pelvic Cancer Drug Market Trends
Table 170. Pelvic Cancer Drug Market Drivers
Table 171. Pelvic Cancer Drug Market Challenges
Table 172. Pelvic Cancer Drug Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
Table 176. Authors List of This Report
List of Figures
Figure 1. Product Picture of Pelvic Cancer Drug
Figure 2. Global Pelvic Cancer Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Pelvic Cancer Drug Market Share by Type: 2024 & 2031
Figure 4. Kidney Cancer Product Picture
Figure 5. Uterus Cancer Product Picture
Figure 6. Cervical Cancer Product Picture
Figure 7. Global Pelvic Cancer Drug Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Pelvic Cancer Drug Market Share by Application: 2024 & 2031
Figure 9. Chemotherapy
Figure 10. Radiation Therapy
Figure 11. Targeted Therapy
Figure 12. Global Pelvic Cancer Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Pelvic Cancer Drug Market Size (2020-2031) & (US$ Million)
Figure 14. Global Pelvic Cancer Drug Sales (2020-2031) & (kg)
Figure 15. Global Pelvic Cancer Drug Average Price (US$/g) & (2020-2031)
Figure 16. Pelvic Cancer Drug Report Years Considered
Figure 17. Pelvic Cancer Drug Sales Share by Manufacturers in 2024
Figure 18. Global Pelvic Cancer Drug Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest Pelvic Cancer Drug Players: Market Share by Revenue in Pelvic Cancer Drug in 2024
Figure 20. Pelvic Cancer Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Pelvic Cancer Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America Pelvic Cancer Drug Sales Market Share by Country (2020-2031)
Figure 23. North America Pelvic Cancer Drug Revenue Market Share by Country (2020-2031)
Figure 24. United States Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe Pelvic Cancer Drug Sales Market Share by Country (2020-2031)
Figure 27. Europe Pelvic Cancer Drug Revenue Market Share by Country (2020-2031)
Figure 28. Germany Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Pelvic Cancer Drug Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific Pelvic Cancer Drug Revenue Market Share by Region (2020-2031)
Figure 35. China Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Latin America Pelvic Cancer Drug Sales Market Share by Country (2020-2031)
Figure 43. Latin America Pelvic Cancer Drug Revenue Market Share by Country (2020-2031)
Figure 44. Mexico Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Brazil Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Argentina Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Colombia Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Middle East and Africa Pelvic Cancer Drug Sales Market Share by Country (2020-2031)
Figure 49. Middle East and Africa Pelvic Cancer Drug Revenue Market Share by Country (2020-2031)
Figure 50. Turkey Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Saudi Arabia Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. UAE Pelvic Cancer Drug Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. Global Sales Market Share of Pelvic Cancer Drug by Type (2020-2031)
Figure 54. Global Revenue Market Share of Pelvic Cancer Drug by Type (2020-2031)
Figure 55. Global Pelvic Cancer Drug Price (US$/g) by Type (2020-2031)
Figure 56. Global Sales Market Share of Pelvic Cancer Drug by Application (2020-2031)
Figure 57. Global Revenue Market Share of Pelvic Cancer Drug by Application (2020-2031)
Figure 58. Global Pelvic Cancer Drug Price (US$/g) by Application (2020-2031)
Figure 59. Pelvic Cancer Drug Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
